GLOW

GHK-Cu is the bulk of the vial and does most of the cosmetic work, carrying copper into cells and driving transcription of collagen I and III, elastin, decorin and the antioxidant enzymes superoxide dismutase and metallothionein. BPC-157 contributes angiogenesis and cytoprotection through VEGFR2 and nitric oxide signalling, which is the part credited with tendon, gut and general soft-tissue repair. TB-500 is an actin-sequestering fragment of thymosin beta-4 that promotes cell migration into a healing site and reduces fibrotic scarring, so it handles the remodelling half of the same job. Because the ratio is roughly five parts GHK-Cu to one part each of the other two, every dose you draw is dominated by copper peptide - a typical ten-unit dose from a 70 mg vial reconstituted in 3 mL delivers about 1,667 mcg of GHK-Cu against roughly 333 mcg each of BPC-157 and TB-500. Nothing about that ratio came from a dose-finding study; it is a vendor formulation choice that the rest of the market copied.

Targets: Copper transport and cellular copper delivery, Collagen I / III, elastin and decorin gene expression, VEGFR2 and nitric oxide signalling, G-actin sequestration and cell migration, SOD and metallothionein

• · This is 10 to 15 units on a U-100 syringe from a 70 mg vial in 3 mL. It works out to roughly 1,667 to 2,500 mcg of GHK-Cu, 333 to 500 mcg of BPC-157 and 333 to 500 mcg of TB-500 per dose. The BPC-157 and TB-500 numbers sit inside their normal standalone bands; the GHK-Cu number sits at the top of its standalone band, which is the part that limits the cycle.
• · Ten units daily with two days off cuts weekly copper exposure by about thirty percent while keeping BPC-157 near 1.7 mg per week and TB-500 near 1.7 mg per week, which is close to standalone TB-500 maintenance dosing. This is the sensible pattern if you want to run longer than four weeks.
• · Five units from a 70 mg vial in 3 mL, giving about 833 mcg GHK-Cu plus 167 mcg each of BPC-157 and TB-500. The GHK-Cu injection-site reaction is dose-related, so starting low tells you how badly you will react before you commit to a full dose.
• · Used for hair and for specific tendon or scar sites. Understand that GHK-Cu commonly leaves a brown or blue-grey mark at the injection site that can persist for weeks, which is a serious consideration on a hairline or anywhere visible. Never inject into a joint space or into the body of a tendon.

Work out your exact syringe units →

• very commonInjection-site pain, redness and residual brown or blue-grey staining— Driven almost entirely by the GHK-Cu component. Marks can persist for weeks. This is the single most reported complaint with GLOW.
• uncommonMetallic taste or nausea shortly after injection— A signal that the copper load is too high. Reduce the dose or shorten the run.
• uncommonFatigue or headache on longer runs— Often reported around week three to four and usually attributed to copper-zinc imbalance.
• uncommonFlushing or lightheadedness immediately after injection— Passes within minutes. More common at doses above 15 units.
• uncommonLoose stools or mild gut upset— Usually attributed to the BPC-157 arm and typically settles within a week.
• rareCopper accumulation and disturbed copper-zinc balance— Not documented at these doses but mechanistically plausible on continuous long-term use, and the reason the cycle is capped.

• Wilson's disease or any condition of impaired copper excretion - injecting a copper complex here is directly dangerous and this is the hard stop for the whole blend.
• Known copper allergy or hypersensitivity.
• Active or recent malignancy - GHK-Cu and BPC-157 are both pro-angiogenic.
• Pregnancy and breastfeeding.
• Drug-tested athletes - BPC-157 and TB-500 are both WADA-prohibited.

• redundantghk-cu — The vial already contains 50 mg of GHK-Cu, which is more than most standalone vials hold. Adding separate injectable GHK-Cu on top is straightforward copper double-dosing and is the most common way people get into trouble with this blend.
• redundantbpc-157 — Running standalone BPC-157 alongside GLOW is double-dosing. If you want more BPC-157 than the blend delivers, the honest answer is to stop the blend and buy the components separately.
• redundanttb-500 — Same problem in the other direction. Adding a standard 2 mg twice-weekly TB-500 protocol on top of daily GLOW takes weekly TB-500 well above anything anyone has data for.
• redundantthymosin-beta-4 — TB-500 is a fragment of thymosin beta-4 and hits the same actin-sequestration target. Running both is one mechanism paid for twice.
• redundantklow — KLOW is GLOW plus KPV. Running both simply doubles the three shared components.
• cautionZinc supplementation — Zinc and copper compete for the same transport pathways. You want zinc alongside a copper run to stop the ratio drifting, but very high-dose zinc taken simultaneously will blunt what you are paying for. 15 to 30 mg daily is the usual compromise.
• cautionCopper-containing multivitamins — Adds to a copper load that is already the limiting factor. Drop supplemental copper for the duration of the run.

• · Read the actual vial label and recompute mg/mL every time you buy from a new vendor - a dose of GLOW is not a portable number.
• · Serum copper and ceruloplasmin if you run beyond eight weeks or go back-to-back without a break.
• · Photograph skin and hairline at baseline, since the effects you are paying for are slow and easy to talk yourself into.
• · Watch injection sites for staining that is not resolving, and rotate aggressively.
• · Track metallic taste, nausea and unexplained fatigue as early copper-overload signals.

None of the three components is an approved drug for human use, and a blend of three unapproved substances is not compoundable regardless of the status of any one of them. Sold entirely as a research chemical. In April 2026 the FDA removed BPC-157, TB-500, GHK-Cu and KPV from the Category 2 bulk drug substances list, and on 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6 to recommend BPC-157 and TB-500 for the 503A Bulks List - a non-binding vote the FDA has not acted on, and one that GHK-Cu was not part of. BPC-157 and TB-500 are both prohibited in sport under WADA.

• Pickart & Margolina 2018, regenerative and protective actions of the GHK-Cu peptide, International Journal of Molecular Sciences (review)
• Sikiric et al., stable gastric pentadecapeptide BPC 157 cytoprotection reviews covering tendon, gut and vascular models (review)
• Goldstein, Hannappel & Kleinman, thymosin beta-4 actin sequestration and tissue repair (review)
• Vendor certificates of analysis and product labels for GLOW blend vials in 50 mg and 70 mg presentations (other)
• FDA Pharmacy Compounding Advisory Committee, 23 July 2026 votes on BPC-157 and TB-500 (guideline)

The Core entry says GHK-Cu drives collagen transcription. The layer under that is what makes GHK unusual: it is not a receptor ligand in the ordinary sense. Pickart's gene-expression work reports GHK modulating expression of thousands of human genes, resetting fibroblast transcription toward a younger phenotype rather than agonising a single target, with copper delivery as the switch. Copper is a required cofactor for lysyl oxidase, the enzyme that cross-links collagen and elastin, and for superoxide dismutase 1. That is the honest mechanistic reason a copper peptide improves skin quality where a plain peptide does not - you are supplying the metal two structural enzymes cannot work without, into cells that are peptidase-rich and metal-poor. It is also why the effect has a ceiling and a cost, because the same copper feeding lysyl oxidase is a redox-active transition metal being pushed into tissue daily. BPC-157 is the component with the biggest gap between confidence and evidence. It has no identified receptor. Nobody has cloned or characterised a BPC-157 binding site, and every mechanism attributed to it is downstream observation: upregulation and internalisation of VEGFR2, activation of the VEGFR2-Akt-eNOS pathway producing nitric oxide, modulation of the nitric oxide system in both directions depending on baseline, and interaction with the FAK-paxillin pathway in tendon fibroblasts. The clinical picture from rodent work - broad, fast, hard to dose-relate - is exactly what you would expect from something acting on vascular tone and endothelial recruitment rather than on a specific cell type. The famously flat dose-response curve is consistent with that, and equally consistent with an effect being over-read. TB-500 sequesters G-actin. Thymosin beta-4 is the principal actin-sequestering protein in most mammalian cells and sits at genuinely high intracellular concentrations, which is the part people skip: you are adding a fragment of an abundant intracellular protein to the extracellular space and expecting it to signal. The proposed mechanism runs through actin monomer availability at the leading edge of migrating cells, promoting endothelial and keratinocyte migration, plus reported effects on inflammation resolution and autophagy. Whether a seven-residue fragment reproduces the full protein's behaviour is not settled, and the ophthalmic trial programme that generated real human data used full-length thymosin beta-4, not the fragment in this vial. The interaction that actually matters between the three is not synergy, it is arithmetic. At roughly five-to-one-to-one, every dose is a copper dose with two repair peptides riding along.

The failure mode that actually happens is not toxicity. It is a stained abdomen and a wasted eight weeks. Injection-site staining is the most common complaint by a wide margin. GHK-Cu leaves brown or blue-grey marks that persist for weeks, sometimes months, and they are dose-related. People inject into the same two convenient spots and then discover they have a permanent-looking patch. Rotate across the whole abdomen and both flanks from day one, and never use this blend anywhere visible. Injecting it into a hairline for hair results is a real practice and a genuinely bad idea for anyone who does not want a visible mark at their scalp margin. The second failure is dose arithmetic. A dose of GLOW is not a portable number, and the unit counts people quote on forums are worthless without the vial they came from. Vendors sell 50 mg and 70 mg presentations, some label the milligram figure as total and some as per component, and the same name from two suppliers can differ several-fold in what you inject. Recompute mg/mL from your own label every time you buy. If the label does not let you work out per-component amounts, you do not know your copper dose and you should not be dosing. The third is copper stacking without noticing. Someone runs GLOW, adds a standalone GHK-Cu vial because they want more skin effect, keeps taking a multivitamin with 2 mg of copper in it, and has quietly tripled their exposure. Metallic taste, nausea and unexplained week-three fatigue are the early signals, and they get dismissed as unrelated. They are not unrelated. The fourth is running back-to-back indefinitely. The cycle cap is not superstition, it is bile-limited copper excretion. Continuous use also hits diminishing returns as cellular copper uptake downregulates, so a permanent run buys accumulating risk in exchange for a fading effect. The fifth is expecting the wrong timeline and then escalating. Skin texture and fine lines are judged at eight to twelve weeks. Nothing you see at week two is the peptide. People who jump to fifteen or twenty units in week three are raising their copper load in response to a timeline that was never going to deliver. The sixth is buying it at all when you wanted one component. If your problem is a tendon, you want BPC-157 daily, TB-500 weekly and zero copper. GLOW cannot give you that. The fixed ratio is not a minor inconvenience, it is the product's defining limitation. The most serious failure, though rare, is undiagnosed impaired copper handling. Wilson's disease is often silent until adulthood and injecting a copper complex is a direct route to harm in someone who has it. A baseline LFT and ceruloplasmin before a first long run is cheap insurance against the one thing on this page that could genuinely hurt you.

1. 1.167 mgDays 1 to 5 — Five units from a 70 mg vial in 3 mL - about 833 mcg GHK-Cu with 167 mcg each of BPC-157 and TB-500. The point is not tolerance-building, it is finding out how badly you stain and bruise before you commit, because the GHK-Cu site reaction is dose-related and the marks last weeks.
2. 2.333 mgDays 6 to 14 — Ten units. Roughly 1,667 mcg GHK-Cu, 333 mcg BPC-157, 333 mcg TB-500. This is what almost everyone actually runs and there is no evidence going past it does more. Metallic taste or nausea here means the copper is too high for you, and the correct response is to drop back to step one rather than push through.
3. 3.5 mgWeek 3 onward, optional and rarely worth it — Fifteen units, taking daily GHK-Cu to about 2,500 mcg - above the top of the standalone injectable band, and it shortens the cycle you can safely run. The extra BPC-157 and TB-500 is marginal; the extra copper is not. Most people who escalate here are impatient about skin results that were always going to take eight to twelve weeks.
4. 2.333 mgWeeks 4 to 8 if continuing — Drop to five days on, two days off at ten units. Cuts weekly copper by about thirty percent while holding BPC-157 near 1.7 mg per week and TB-500 near 1.7 mg per week, close to standalone TB-500 maintenance. This is the step that lets a run reach eight weeks without the copper arithmetic getting ugly.

• Lysyl oxidase (copper-dependent cross-linking enzyme)

  Copper delivered by GHK acts as the obligate cofactor. Without adequate copper this enzyme cannot cross-link newly synthesised collagen and elastin, which is why copper delivery rather than the peptide backbone is the load-bearing part of the GHK-Cu story.

• Superoxide dismutase 1 and metallothionein

  Copper-dependent antioxidant capacity is raised. This is the mechanism behind the antioxidant claims made for the blend, and it is real, but it is a nutrient-cofactor effect rather than a drug effect.

• Fibroblast transcriptional programme - collagen I and III, elastin, decorin, glycosaminoglycans

  Broad upregulation of matrix synthesis genes across GHK gene-expression studies. Not a single-receptor action, which is why the effects are wide and slow rather than sharp.

• VEGFR2 (KDR)

  The BPC-157 arm. Increased receptor expression and activation of the VEGFR2-Akt-eNOS axis, producing nitric oxide, vasodilation and angiogenesis into damaged tissue. No direct binding of BPC-157 to VEGFR2 has been demonstrated - the receptor is downstream, not the target.

• Nitric oxide synthase system

  BPC-157 modulates NO signalling bidirectionally in rodent models, opposing both L-NAME-induced hypertension and L-arginine-induced hypotension. This is the most reproducible pharmacological signature it has and also the least specific.

• G-actin (monomeric actin)

  The TB-500 arm. Sequesters actin monomers and shifts the polymerisation equilibrium, proposed to mobilise cell migration into a wound bed and reduce fibrotic scarring. Reported binding for full-length thymosin beta-4 is in the micromolar range; no verified affinity figure exists for the marketed fragment.

• No identified BPC-157 receptor

  Listed explicitly because it is the most important gap in this blend's pharmacology. Twenty-five years of publication and no cloned or characterised binding site. Every BPC-157 mechanism here is an observed downstream change, not a receptor interaction.

Days 1 to 3: nothing systemic. What you get immediately is the injection site telling you how you react to copper - sting on injection, redness, and often a bruise-like mark that starts brown and darkens. A metallic taste in the first hour is a copper signal at your current dose, not a novelty. Week 1: injection-site tolerance either settles or does not. Some people report skin feeling smoother or better hydrated within days, which is soon enough to be plausible only as a hydration or inflammatory change rather than new matrix. Weeks 2 to 4: the soft-tissue effects show up here if they are going to. Reduced ache in a nagging tendon, faster settling of minor injuries, and for some people gut changes from the BPC-157 arm. This is also when copper-related fatigue or headache appears. Weeks 4 to 8: skin texture and tone become assessable. Collagen synthesis, remodelling and cross-linking are slow and there is no version of this that is faster. Weeks 8 to 12: the honest assessment point for the cosmetic and hair claims, which is why you photograph at baseline. Judging by memory at week ten will tell you whatever you want to hear. After stopping: injection-site marks fade over weeks to months. Skin quality from new collagen persists a while and then resumes the trajectory it was on. The TB-500 arm has the longest tail because its tissue effects outlast its plasma presence by days, so the last dose is not the last day it is doing anything.

Everything worth saying here is a subtraction, not an addition. The vial already contains three peptides and the only stacking decisions that matter are what to leave out. Zinc at 15 to 30 mg daily is the one genuine addition, and it is a countermeasure rather than a synergist. Take it several hours away from the injection, and keep taking it through the off-cycle rather than stopping when the vial does, because that is when the ratio is recovering. Do not run 50 mg or more trying to be safe - you will blunt the copper uptake you are paying for and can push the imbalance the other way. Drop any copper-containing multivitamin for the duration. Most multis and B-complexes carry 0.9 to 2 mg of copper, a meaningful addition to a 1.7 mg daily injected load. High-dose vitamin C is worth a thought rather than a panic. Ascorbate reduces Cu(II) to Cu(I) and can drive Fenton chemistry in vitro, and very high oral intakes impair copper absorption. This is plausible rather than documented, but taking several grams of vitamin C at the same time as a copper peptide injection is an unnecessary experiment. Normal dietary or single-gram supplement intake is not the concern. Collagen peptides plus ordinary vitamin C are the sensible complements if skin is the goal, because you are supplying substrate and a hydroxylase cofactor for a transcriptional programme the blend is upregulating. That is coherent, cheap and low risk, and it is the only stack here with an obvious rationale. Do not stack GLOW with KLOW, Wolverine, or standalone GHK-Cu, BPC-157, TB-500 or thymosin beta-4. Each doubles a component already in the vial. GLOW plus Wolverine is the common error: it doubles both repair peptides and adds nothing you could not get by taking more of one product. GH secretagogue stacks such as ipamorelin with CJC-1295 do not conflict pharmacologically and are frequently run alongside. There is no data on the combination and no mechanism by which they interfere. If you are on penicillamine, trientine or zinc acetate for a copper-handling condition, this is not a stacking question - it is a contraindication.

Against standalone GHK-Cu: GLOW is mostly GHK-Cu, so the cosmetic effect you are buying is largely the same one at a dose sitting at the top of the standalone band. The blend adds two repair peptides you may not want and removes your ability to reduce copper independently. If skin is the only goal, standalone GHK-Cu is more controllable, and topical GHK-Cu is the form with actual controlled human data behind it. Against Wolverine: Wolverine is the BPC-157 and TB-500 half of GLOW without the copper. For an injury it is straightforwardly the better tool - same repair components, higher per-dose amounts of both, no copper ceiling, no staining, no cycle cap driven by a heavy metal. GLOW beats it only if you genuinely want the skin effect. Against KLOW: KLOW is GLOW plus KPV, aimed at inflammation and gut rather than skin. The copper arithmetic and cycle limit are identical. Choose KLOW if inflammation is the target, GLOW if appearance is. Against buying the three components separately: separate vials cost more and mean three injections or one carefully drawn mixed syringe, but they let you run BPC-157 daily, TB-500 weekly and GHK-Cu for twenty days out of each cycle - which is how each compound is dosed by anyone who has looked at them individually. That is a materially better protocol. GLOW's honest selling point is one purchase and one injection, and convenience is a legitimate reason to choose something as long as you know that is what you are choosing. Against doing nothing for skin: topical tretinoin has decades of controlled human data for photoaged skin, costs a fraction of this, and does not involve injecting a transition metal. Anyone buying GLOW purely for facial skin quality who has not tried a retinoid first is paying more for weaker evidence.

$60–$140/month. A 70 mg vial in 3 mL gives roughly thirty ten-unit doses, so one vial is close to one month at the standard protocol. Grey-market vial pricing has generally sat in the sixty to one hundred and forty dollar band, the spread reflecting purity claims and third-party testing rather than dose. Add ten to twenty dollars for bacteriostatic water, syringes and the zinc you should be taking. These are observed market ranges rather than figures verified in this session, and pricing in this category moves with enforcement activity.

• ?The five-to-one-to-one ratio has no published basis of any kind. It appears to be a vendor formulation choice the rest of the market copied, and I found nothing resembling a dose-finding rationale for it.
• ?No pharmacokinetic data exists for GHK-Cu given subcutaneously in humans. Everything quoted about GHK clearance refers to the free tripeptide in plasma, while the copper it delivers follows a much slower route that is not characterised at these repeated doses.
• ?TB-500's identity genuinely varies across vendors. Some ship the short acetylated actin-binding fragment, some ship full-length thymosin beta-4, and the two differ in molecular weight by roughly a factor of six, so a milligram figure means different molar doses depending on what arrived.
• ?No verified binding affinity for TB-500 or full-length thymosin beta-4 to G-actin was resolved in this session, so those affinity fields are left empty rather than filled with a remembered number.
• ?Molecular weights for all three components are deliberately omitted. They are exactly the kind of number that gets invented, and none was verified here.
• ?The claim that cellular copper uptake downregulates after weeks of continuous exposure is standard copper transporter physiology but I did not resolve a primary source for it at these doses and by this route.
• ?The copper-to-zinc ratio thresholds in the bloodwork section come from general clinical practice around copper-zinc balance, not from any study of injected GHK-Cu. Treat them as reasonable trigger points, not validated cutoffs.
• ?Whether daily subcutaneous GHK-Cu meaningfully raises total body copper in someone with normal biliary excretion is unknown. The cycle caps here are precautionary reasoning from copper physiology, not measurement.
• ?Injection-site staining is universally reported by users but I found no published characterisation, so its duration and whether it is ever permanent remain anecdotal.
• ?Vendor content and ratio accuracy for blends is widely questioned, but I did not verify any specific independent testing programme in this session.
• ?No human trial of GLOW, or of any two of its three components together, exists. The trials array is empty for that reason rather than by omission.
• ?The cost range comes from general market observation and was not verified against current vendor pricing in this session.
• ?Component sequences in the modifications array are established chemistry but were not independently resolved this session, which is why the sequence verified flag is false.

• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data Pickart L, Margolina A, International Journal of Molecular Sciences, 2018 · PMID 29986520

  The reference review for the GHK-Cu component, which is the bulk of this vial. Sets out the gene-expression argument for GHK as a broad transcriptional modulator rather than a receptor ligand. Pickart holds commercial interests in copper peptide products, which is not a reason to dismiss the work but is a reason to read it as an advocate's review.

• GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration Pickart L, Vasquez-Soltero JM, Margolina A, BioMed Research International, 2015 · PMID 26236730

  The gene-modulation claims quoted in blend marketing come from here and its companions. Worth reading directly if only to see how much of the GHK evidence base is in vitro fibroblast and gene-array work rather than clinical outcome data.

• The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health Pickart L, Vasquez-Soltero JM, Margolina A, Oxidative Medicine and Cellular Longevity, 2012 · PMID 22666519

  Source for the superoxide dismutase and metallothionein claims, and for the observation that plasma GHK falls with age - the premise the entire product category rests on.

• Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, Zhang W, Wang S, Wang Z, Hao Q, Zhang C, Gao Y, Gu J, Zhang Y, Li W, Li M, Frontiers in Pharmacology, 2022 · PMID 36588717

  The only real ADME study on BPC-157 and the source of every hard PK number in this record: elimination half-life under 30 minutes, intramuscular bioavailability 14 to 19 percent in rats and 45 to 51 percent in dogs, urine and bile as excretory routes, rapid hydrolysis to amino acids. Animal only - there is still no human PK study.

• Stable Gastric Pentadecapeptide BPC 157 and Wound Healing Seiwerth S, Milavic M, Vukojevic J, Gojkovic S, Krezic I, Vuletic LB, Pavlov KH, Petrovic A, Sikiric S, Vranes H, Sikiric P, et al, Frontiers in Pharmacology, 2021 · PMID 34267654

  Representative of the Sikiric group's BPC-157 output, which is the large majority of the BPC-157 literature. Read it for the mechanism claims, but note that a single research group producing nearly all the positive data on a compound is itself a limitation, and that no completed human efficacy trial exists.

• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM, Current Reviews in Musculoskeletal Medicine, 2025 · PMID 40789979

  A recent independent review from outside the Sikiric group, and the more useful counterweight if you want an honest read on how far the BPC-157 evidence actually reaches for the tendon and joint claims this blend is sold on.

• Advances in the basic and clinical applications of thymosin beta4 Goldstein AL, Kleinman HK, Expert Opinion on Biological Therapy, 2015 · PMID 26096726

  The reference review for the TB-500 arm, with the important caveat that it is about full-length thymosin beta-4. The fragment sold as TB-500 inherits this evidence by assertion, not by demonstration.

• Animal studies with thymosin beta, a multifunctional tissue repair and regeneration peptide Philp D, Kleinman HK, Annals of the New York Academy of Sciences, 2010 · PMID 20536453

  The animal wound-healing and anti-fibrotic data behind the remodelling claims made for the TB-500 component.

• Effect of locally injected medications on healing of pad wounds in dogs Swaim SF, Vaughn DM, Kincaid SA, Morrison NE, Murray SS, Woodhead MA, Hoffman CE, Wright JC, Kammerman JR, American Journal of Veterinary Research, 1996 · PMID 8669775

  Included because it is one of the few studies that actually injected a tripeptide-copper complex rather than applying it topically. Dogs, pad wounds, 1996 - but closer to what you are doing with this vial than any of the cosmetic topical work usually cited for it.